A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma

Hepatology

Volumn 60, Issue 4, 2014, Pages 1302-1313

  Aihara, Arihiro ^a   Huang, Chiung Kuei ^a   Olsen, Mark J ^b   Lin, Qiushi ^c   Chung, Waihong ^a   Tang, Qi ^c   Dong, Xiaoqun ^c   Wands, Jack R ^a  

^a Liver Research Center Brown University Medical School   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTYL (ASPARAGINYL) BETA HYDROXYLASE; CELL SURFACE PROTEIN; MO I 1100; NOTCH RECEPTOR; OXYGENASE; OXYGENASE INHIBITOR; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG; ASPARTIC ACID 2-OXOGLUTARATE-DEPENDENT DIOXYGENASE; ENZYME INHIBITOR; FURAN DERIVATIVE; MEMBRANE PROTEIN; MIXED FUNCTION OXIDASE; MO-I-1100; SULFONIC ACID DERIVATIVE; TUMOR MARKER;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CATALYSIS; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURFACE; CELL TRANSFORMATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; LIVER NEOPLASMS; METABOLISM; NEOPLASM METASTASIS; NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; FURANS; HETEROGRAFTS; HUMANS; IN VITRO TECHNIQUES; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, NUDE; MIXED FUNCTION OXYGENASES; NEOPLASM METASTASIS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SULFONIC ACIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84927748882     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27275     Document Type: Article

References (38)

1. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999;229:790-799; discussion, 799-800.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
4. Jia S, VanDusen WJ, Diehl RE, Kohl NE, Dixon RA, Elliston KO, et al. cDNA cloning and expression of bovine aspartyl (asparaginyl) beta-hydroxylase. J Biol Chem 1992;267:14322-14327.
5. Engel J. EGF-like domains in extracellular matrix proteins: localized signals for growth and differentiation? FEBS Lett 1989;251:1-7.
6. Shimoda M, Tomimaru Y, Charpentier KP, Safran H, Carlson RI, Wands J. Tumor progression-related transmembrane protein aspartate-beta-hydroxylase is a target for immunotherapy of hepatocellular carcinoma. J Hepatol 2012;56:1129-1135.
7. Lavaissiere L, Jia S, Nishiyama M, de la Monte S, Stern AM, Wands JR, Friedman PA. Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest 1996;98:1313-1323.
8. Zaret KS, Grompe M. Generation and regeneration of cells of the liver and pancreas. Science 2008;322:1490-1494.
9. Wang J, de la Monte SM, Sabo E, Kethu S, Tavares R, Branda M, et al. Prognostic value of humbug gene overexpression in stage II colon cancer. Hum Pathol 2007;38:17-25.
10. Wang K, Liu J, Yan ZL, Li J, Shi LH, Cong WM, et al. Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology 2010;52:164-173.
11. Ince N, de la Monte SM, Wands JR. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res 2000;60:1261-1266.
12. Nishiyama M, Wands JR. Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma. Biochem Biophys Res Commun 1992;183:280-285.
13. Shimoda M, Tomimaru Y, Charpentier KP, Safran H, Carlson RI, Wands J. Tumor progression-related transmembrane protein aspartate-beta-hydroxylase is a target for immunotherapy of hepatocellular carcinoma. J Hepatol 2012;56:1129-1135.
14. Wang QP, VanDusen WJ, Petroski CJ, Garsky VM, Stern AM, Friedman PA. Bovine liver aspartyl beta-hydroxylase. Purification and characterization. J Biol Chem 1991;266:14004-14010.
15. Gronke RS, Welsch DJ, VanDusen WJ, Garsky VM, Sardana MK, Stern AM, Friedman PA. Partial purification and characterization of bovine liver aspartyl beta-hydroxylase. J Biol Chem 1990;265:8558-8565.
16. Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, et al. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol;52:63-71.
17. de la Monte SM, Tong M, Carlson RI, Carter JJ, Longato L, Silbermann E, Wands JR. Ethanol inhibition of aspartyl-asparaginyl-beta-hydroxylase in fetal alcohol spectrum disorder: potential link to the impairments in central nervous system neuronal migration. Alcohol 2009;43:225-240.
18. Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, Wands JR. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006;44:446-457.
19. Sepe PS, Lahousse SA, Gemelli B, Chang H, Maeda T, Wands JR, de la Monte SM. Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility. Lab Invest 2002;82:881-891.
20. Branda M, Wands JR. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 2006;43:891-902.
21. Calvisi DF, Frau M, Tomasi ML, Feo F, Pascale RM. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison. Biochim Biophys Acta 2012;1826:215-237.
22. Strazzabosco M. Notch signaling in hepatocellular carcinoma: guilty in association! Gastroenterology 2012;143:1430-1434.
23. Dill MT, Tornillo L, Fritzius T, Terracciano L, Semela D, Bettler B, et al. Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology 2013;57:1607-1619.
24. Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 2012;143:1660-1669 e1667.
25. Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 2013;144:1530-1542.e12.
26. Zhou L, Zhang N, Song W, You N, Li Q, Sun W, et al. The significance of Notch1 compared with Notch3 in high metastasis and poor overall survival in hepatocellular carcinoma. PLoS One 2013;8:e57382.
27. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-233.
28. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010;29:4989-5005.
29. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998;27:951-958.
30. Wands JR, Kim M. WNT/beta-catenin signaling and hepatocellular carcinoma. Hepatology 2014 Feb 20. doi: 10.1002/hep.27081. [Epub ahead of print].
31. Longato L, de la Monte S, Kuzushita N, Horimoto M, Rogers AB, Slagle BL, Wands JR. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology 2009;49:1935-1943.
32. Tomimaru Y, Koga H, Yano H, de la Monte SM, Wands JR, Kim M. Up-regulation of TCF-4 isoform-responsive target genes in hepatocellular carcinoma. Liver Int 2013;33:1100-1112. [Revised version under review].
33. de la Monte SM, Tamaki S, Cantarini MC, Ince N, Wiedmann M, Carter JJ, et al. Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol 2006;44:971-983.
34. Gundogan F, Bedoya A, Gilligan J, Lau E, Mark P, De Paepe ME, de la Monte SM. siRNA inhibition of aspartyl-asparaginyl beta-hydroxylase expression impairs cell motility, Notch signaling, and fetal growth. Pathol Res Pract 2011;207:545-553.
35. Maeda T, Sepe P, Lahousse S, Tamaki S, Enjoji M, Wands JR, de la Monte SM. Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol 2003;38:615-622.
36. Zender S, Nickeleit I, Wuestefeld T, Sorensen I, Dauch D, Bozko P, et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell 2013;23:784-795.
37. Shih Ie M, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007;67:1879-1882.
38. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006;7:678-689.